THE eagerly anticipated return of stock car racing to one of its fabled homes has been pushed back, but a promoter for the sport is still feeling optimistic. Prime Minister Boris Johnson addressed the nation on Monday to tell the public how the Government would ease Covid-19 restrictions in the coming months, The roadmap out of the country s third lockdown has provoked a variety of reactions from education officials, businesses and the world of sports. One particular firm that has been impacted adversely is stock car racing promoters, Startrax. The team has been working hard since the start of this year to transform Odsal Stadium - former home of the Bradford Bulls - in preparation for the return of the sport to Bradford for the first time in just over 23 years.
WORK is progressing rapidly towards the “finishing line” of returning Bradford’s most famous venue to its former glory. Odsal Stadium has been out of action since main occupiers, Bradford Bulls, said goodbye to their fabled home on Sunday, September 1, 2019. More than 7,000 fans turned up for that game against Sheffield Eagles, before the rugby league side made the move to Dewsbury. The famous bowl has been silent ever since. But the murmurs of rumour, and then the concrete evidence of a certain much-loved sport returning to the stadium after decades away, have now turned to the hum of machinery and the chitter-chatter of workers.
Editorial Letters – Week ending December 11, 2020 lbknews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lbknews.com Daily Mail and Mail on Sunday newspapers.
Genedata Collaborates with AstraZeneca to Boost Impact of Cellular Imaging in Biopharma Drug Discovery
Share:
Award-winning Genedata Imagence HCS imaging enterprise software rolled out to AstraZeneca R&D sites globally with the aim of improving the identification of new drug candidates and drug targets
Basel, Switzerland December 17, 2020
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Genedata Imagence®, its deep learning-based image analysis software solution, has been licensed by global biopharmaceutical company AstraZeneca for use in high content screening (HCS) across its R&D sites. AstraZeneca is the latest addition to the rapidly growing number of research-driven companies benefiting from the award-winning Genedata Imagence, a component of the Genedata Biopharma Platform.